Agilent Technologies (A) Stock Price, Quote & News

Company Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufact...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 800 227 9770

Website: www.agilent.com

Address:

5301 Stevens Creek Boulevard, Santa Clara, United States

OnlyFibs Apr. 19 at 1:39 AM

$A — Agilent Technologies. $7.3–7.5B revenue guided for FY2026. Non-GAAP EPS $5.90–6.04. Book-to-bill above 1.0 for 8 consecutive quarters. Q1 revenue +7%, EPS +4%, guidance raised. 1W chart shows a 4-year symmetrical triangle at the apex — forced resolution approaching. RSI at lowest level since COVID crash. Weekly buy volume building. 🐂 Upper diagonal breaks → $129 → $137 → triangle target $150+ 🐻 China deteriorates + upper diagonal rejects → lower diagonal $108 → $102 ⚠️ 20x forward non-GAAP EPS on 7% revenue growth — historically cheap for Agilent. Triangle apex means the range-bound period ends. RSI and book-to-bill both bullish. #A #Agilent #LifeScience #hovdid

0 · Reply

NorthStarStats Apr. 15 at 9:57 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $LEGN Score 100, $SLN Score 100, $A Score 100, $IMVT Score 98, $CG Score 95

0 · Reply

SuperGreenToday Apr. 8 at 2:12 PM

$A Share Price: $117.14 Contract Selected: Aug 21, 2026 $115 Calls Buy Zone: $9.27 – $11.45 Target Zone: $15.80 – $19.32 Potential Upside: 61% ROI Time to Expiration: 134 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

WhaleAndState Apr. 6 at 10:10 AM

$A filed an 8-K amendment — stock at $115.48, market cap $32.7B. The filing contains no material detail beyond the headline. Expect continued upward movement as market sentiment remains positive.

0 · Reply

tcamp923 Mar. 26 at 8:04 PM

$A $TTOO Agilent is flagging on the weekly frame news gets price back over 120+ imo

0 · Reply

Estimize Mar. 25 at 3:01 PM

Wall St is expecting 1.41 EPS for $A Q2 [Reporting 05/26 AMC] http://www.estimize.com/intro/a?chart=historical&metric_name=eps&utm_content=

0 · Reply

Zefram Mar. 21 at 12:14 AM

$TTOO $A rip all those theories of options insider trading from trash camp... lul.. does that guy get anything right? being punished by losing all his money isn't enough to make him a humbled man... the guy has zero shame. this website is filled with entertainment... and he's like karl malone... he always delivers.

0 · Reply

Zefram Mar. 19 at 10:36 PM

$TTOO $A i trade 0 dte options almost every day.. i've probably made more money trading in the last month than you have all decade. i like how you haven't made money trading.. but some how you think you're better at this than me... LOL you're goofy bro. i walked you through TTOO and somehow you still lost your entire retirement. literally play by play... made it easy for you... and you still lost hundreds of thousands. what a moron. LOL

0 · Reply

Zefram Mar. 19 at 10:34 PM

$TTOO $A isn't it funny that you're on the side of the bagholders.... the masses of bagholders... and they barely interact with your posts too? you'd expect people to not interact or even see my posts.. guys like you block and put your head in the sand. what's your excuse? the only one who actually do interact with yours are other guys who lost everything and are incompetent in the trades like you are.. good way to farm those guys, bro.. birds of a feather. no one respectable or knowledgeable is interacting with your posts. LOL

0 · Reply

Zefram Mar. 19 at 10:14 PM

$TTOO $A what do you call it when you ride a stock down 99.9999%... and keep putting money into it? not dumb? lul k. you could forgive year 1.... but you'd like at year 5 or 6.. or 7... you'd learn from it. but you didnt. LOL that's not dumb? k, bro.

1 · Reply

Agilent Showcases Cancer Research Solutions at AACR 2026

Apr 1, 2026, 8:00 AM EDT - 17 days ago

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

Mar 26, 2026, 8:00 AM EDT - 23 days ago

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

Mar 19, 2026, 8:00 AM EDT - 4 weeks ago

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

Mar 11, 2026, 8:00 AM EDT - 5 weeks ago

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

Mar 9, 2026, 3:09 AM EDT - 5 weeks ago

Agilent to acquire Biocare Medical in $950 million all-cash deal

Mar 9, 2026, 3:05 AM EDT - 5 weeks ago

Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies

Mar 9, 2026, 3:00 AM EDT - 5 weeks ago

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

Feb 25, 2026, 5:24 PM EST - 7 weeks ago

Agilent reports in-line first quarter, says results hurt by US snowstorm

Feb 25, 2026, 4:05 PM EST - 7 weeks ago

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

Feb 23, 2026, 4:15 PM EST - 7 weeks ago

Agilent to Participate in TD Cowen's 46th Annual Health Care Conference

Feb 11, 2026, 4:15 PM EST - 2 months ago

Agilent Announces Cash Dividend of 25.5 Cents per Share

Feb 11, 2026, 8:00 AM EST - 2 months ago

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

Feb 11, 2026, 6:45 AM EST - 2 months ago

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Feb 4, 2026, 8:00 AM EST - 2 months ago

Agilent Showcases Next‑Generation Automated Solutions at SLAS2026

Feb 2, 2026, 4:15 PM EST - 2 months ago

Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

Jan 23, 2026, 8:00 AM EST - 3 months ago

Agilent Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System

Dec 16, 2025, 8:31 AM EST - 4 months ago

Agilent to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 1, 2025, 8:00 AM EST - 4 months ago

Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight

Nov 25, 2025, 1:24 PM EST - 5 months ago

Top small-cap plays for 2026

COHR DG EW TXT VLO

Nov 25, 2025, 1:06 PM EST - 5 months ago

These Analysts Boost Their Forecasts On Agilent After Upbeat Q4 Results

Nov 24, 2025, 4:10 PM EST - 5 months ago

Agilent Reports Fourth-Quarter Fiscal Year 2025 Financial Results

Nov 24, 2025, 4:07 PM EST - 5 months ago

Agilent beats quarterly revenue estimates on strong demand for lab tools

Nov 24, 2025, 1:50 PM EST - 5 months ago

Josh Brown's ‘best stocks in the market': Health Care

LLY MTD TMO XLV

Nov 24, 2025, 8:30 AM EST - 5 months ago

Top Wall Street Forecasters Revamp Agilent Expectations Ahead Of Q4 Earnings

Nov 19, 2025, 4:15 PM EST - 5 months ago

Agilent Announces Cash Dividend of 25.5 Cents Per Share

Nov 18, 2025, 5:10 PM EST - 5 months ago

Agilent to Participate in Citi's 2025 Global Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 5 months ago

Agilent Research Catalyst (ARC) Award Presented to UC Davis for Breakthroughs in Peptide Therapeutics

Oct 30, 2025, 4:15 PM EDT - 6 months ago

Agilent to Announce Fourth-Quarter Fiscal Year 2025 Financial Results on Nov. 24

Oct 27, 2025, 4:15 PM EDT - 6 months ago

Agilent Names Adam S. Elinoff as Chief Financial Officer

Sep 30, 2025, 8:00 AM EDT - 7 months ago

Agilent Announces New Insight Series Alarm Resolution Systems for Airport Security Screening

Sep 29, 2025, 8:00 AM EDT - 7 months ago

Agilent Introduces the Altura Line of Inert HPLC Columns for Superior Results in Biotherapeutic Testing

Sep 22, 2025, 9:00 AM EDT - 7 months ago

Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine

Sep 17, 2025, 4:05 PM EDT - 7 months ago

Agilent Announces Cash Dividend of 24.8 Cents per Share

Sep 11, 2025, 4:15 PM EDT - 7 months ago

Agilent to Participate in 2025 Bank of America Global Healthcare Conference

Sep 9, 2025, 8:00 AM EDT - 7 months ago

Agilent Refurbishment Centers Achieve Top-Level My Green Lab Certification

Sep 8, 2025, 4:30 PM EDT - 7 months ago

Agilent (A) CEO on PFAS Testing Growth & Creating Advanced Instruments for Science

Sep 3, 2025, 8:00 AM EDT - 8 months ago

Agilent to Showcase New Dako Omnis Family at European Congress of Pathology 2025

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Agilent's MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer

Aug 27, 2025, 4:05 PM EDT - 8 months ago

Agilent Reports Third-Quarter Fiscal Year 2025 Financial Results

Aug 27, 2025, 4:03 PM EDT - 8 months ago

Life sciences firm Agilent raises annual revenue outlook

Aug 21, 2025, 4:15 PM EDT - 8 months ago

Agilent to Participate in 2025 Wells Fargo Healthcare Conference

Aug 20, 2025, 8:00 AM EDT - 8 months ago

Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer

Aug 13, 2025, 8:00 AM EDT - 8 months ago

Shane Snyder to Lead New Agilent Center of Excellence at Georgia Tech Focused on Water and the Environment

Aug 4, 2025, 8:00 AM EDT - 9 months ago

Agilent Expands the Dako Omnis Family with Three New Models to Meet Evolving Pathology Lab Needs

Jul 29, 2025, 9:10 AM EDT - 9 months ago

Agilent Tech looks to double investments in India, eyes high-teen growth, CEO says

Jul 17, 2025, 4:30 PM EDT - 9 months ago

Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27

Jul 15, 2025, 8:30 AM EDT - 9 months ago

Agilent Announces CFO Transition

Jun 12, 2025, 8:00 AM EDT - 11 months ago

Agilent to Showcase New Products and Innovations at HPLC 2025

OnlyFibs Apr. 19 at 1:39 AM

0 · Reply

NorthStarStats Apr. 15 at 9:57 AM

0 · Reply

SuperGreenToday Apr. 8 at 2:12 PM

0 · Reply

WhaleAndState Apr. 6 at 10:10 AM

$A filed an 8-K amendment — stock at $115.48, market cap $32.7B. The filing contains no material detail beyond the headline. Expect continued upward movement as market sentiment remains positive.

0 · Reply

tcamp923 Mar. 26 at 8:04 PM

$A $TTOO Agilent is flagging on the weekly frame news gets price back over 120+ imo

0 · Reply

Estimize Mar. 25 at 3:01 PM

Wall St is expecting 1.41 EPS for $A Q2 [Reporting 05/26 AMC] http://www.estimize.com/intro/a?chart=historical&metric_name=eps&utm_content=

0 · Reply

Zefram Mar. 21 at 12:14 AM

0 · Reply

Zefram Mar. 19 at 10:36 PM

0 · Reply

Zefram Mar. 19 at 10:34 PM

0 · Reply

Zefram Mar. 19 at 10:14 PM

1 · Reply

Zefram Mar. 19 at 10:13 PM

$TTOO $A hint: it's not insider trading... it's never been insider trading... it's never been fraud. you just suck at analysis. that's why you keep losing. and you're port is nuked.

0 · Reply

tcamp923 Mar. 19 at 10:12 PM

$A $TTOO hey look another Zefram book post with zero likes Grass is green Water is wet

0 · Reply

tcamp923 Mar. 19 at 10:10 PM

$A $TTOO ok bro can’t read and yeah inside trading is illegal hence the question no I’m not dumb, but your response is asinine

0 · Reply

Zefram Mar. 19 at 9:19 PM

$TTOO $A still remember when he didnt understand what variants of iron condor strats were.. and thought those were insider trades too.. LLOOOOOOL taylor is the biggest clown on these boards.. and it's been hilarious watching him lose money time over time... while trying to tell me that im evil and dumber than him.

0 · Reply

Zefram Mar. 19 at 9:16 PM

$TTOO $A are you dumb? " why are people buying something that will make them money????" within 24 hours?? WHYY???????? do you not know how options work? it's funny your last one was about calls at a certain price and those contracts got slaughtered... and now you're on to a new grift. you're just dumb, man. you dont know how to make money in the market... you have zero insight, even in fields you should have some knowledge in. it's very funny to see you jestering around these boards.. trying to pretend to be an oracle. it must be so mystifying when you think everything is fraud or insider trading.. because you dont know how to make money trading. it can never be that you're completely ignorant and made incorrect analysis... like you did your entire time in ttoo.. IT MUST BE FRAUD or something out of your control. what a weak way to live life. zero agency. zero accountability. pathetic really.

0 · Reply

tcamp923 Mar. 19 at 9:07 PM

$TTOO $A VERY UNUSUAL OPTION ACTIVITY ON AGILENT 3/20 (FRIDAY) OPEX Why is a trader buying/selling deep in the money puts with 1 day to expiration THIS IS AN INSIDE TRADE ‼️🚨

0 · Reply

SuperGreenToday Mar. 17 at 6:32 PM

$A Share Price: $113.65 Contract Selected: Jun 18, 2026 $115 Calls Buy Zone: $4.67 – $5.78 Target Zone: $7.94 – $9.71 Potential Upside: 60% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

CasperPuff Mar. 12 at 5:06 PM

$A just got in

0 · Reply

topstockalerts Mar. 9 at 3:08 PM

Agilent Technologies announced it will acquire privately held clinical pathology firm Biocare Medical for $950 million in cash. The deal strengthens Agilent’s position in immunohistochemistry, a cancer diagnostic technique that uses antibodies to detect abnormal cells. Biocare Medical offers integrated tissue-diagnostics tools used for cancer and infectious disease testing, with government and military laboratories among its customers. Agilent said the acquisition should boost revenue growth and profit margins in the first year while increasing its share of consumables and services sales. The transaction is expected to close by the end of the fourth quarter of 2026, subject to regulatory approval. $A

0 · Reply

OpenOutcrier Mar. 9 at 12:19 PM

$A (+0.0% pre) Agilent to acquire Biocare Medical in $950 million all-cash deal https://ooc.bz/l/95944

0 · Reply

Market Cap	34.44B
Revenue (ttm)	6.95B
Net Income (ttm)	1.30B
EPS (ttm)	N/A
PE Ratio	21.00
Forward PE	19.88
Profit Margin	18.75%
Debt to Equity Ratio	0.44

Volume	4,012,500
Avg Vol	2,313,992
Day's Range	N/A - N/A
Shares Out	282.60M
Stochastic %K	99%
Beta	1.30
Analysts	Strong Sell
Price Target	$162.64